586 Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in extensive-stage small-cell lung cancer (ES–SCLC): RNA sequencing analysis to explore canonical markers of IO activity in CASPIAN | Zendy

AI Assistant Blog Pricing

586 Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in extensive-stage small-cell lung cancer (ES–SCLC): RNA sequencing analysis to explore canonical markers of IO activity in CASPIAN

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.